Meta-Analysis of Duration of Dual Antiplatelet Therapy in Acute Coronary Syndrome Treated With Coronary Stenting
Autor: | Laurence S. Sperling, Henry A. Liberman, Rhanderson Cardoso, Michael C. McDaniel, Marcelo F. Fernandes, Leonardo Knijnik, Abhinav Goyal, Manuel Rivera |
---|---|
Rok vydání: | 2021 |
Předmět: |
Acute coronary syndrome
medicine.medical_specialty Hemorrhage 030204 cardiovascular system & hematology law.invention 03 medical and health sciences 0302 clinical medicine P2Y12 Percutaneous Coronary Intervention Randomized controlled trial law Internal medicine Cause of Death medicine Humans 030212 general & internal medicine Acute Coronary Syndrome Mortality Randomized Controlled Trials as Topic Aspirin Cochrane collaboration Duration of Therapy business.industry Dual Anti-Platelet Therapy Coronary stenting Drug-Eluting Stents medicine.disease Meta-analysis Cardiology Purinergic P2Y Receptor Antagonists Cardiology and Cardiovascular Medicine business Major bleeding Platelet Aggregation Inhibitors medicine.drug |
Zdroj: | The American journal of cardiology. 151 |
ISSN: | 1879-1913 |
Popis: | We aimed to evaluate if a shorter course of DAPT followed by P2Y12 inhibitor monotherapy is as effective as a 12-month course with fewer bleeding events. PubMed, Scopus, and Cochrane Central were searched for randomized controlled trials of ACS patients comparing dual antiplatelet therapy (DAPT) for 1 to 3 months followed by a P2Y12 inhibitor to 12-month DAPT. Quality assessment was performed with the Cochrane Collaboration risk of bias assessment tool. Five randomized clinical trials were included, with a total of 18,046 participants. Antiplatelet strategies were aspirin and P2Y12 inhibitor for 12 months compared with aspirin and P2Y12 inhibitor for 1 to 3 months followed by P212 inhibitor alone. Patients randomized to 1 to 3 months of DAPT followed by P2Y12 inhibitor monotherapy had lower rates of major bleeding (1.42% vs 2.53%; OR 0.53; 95% CI 0.42-0.67; p0.001; I |
Databáze: | OpenAIRE |
Externí odkaz: |